Cargando…

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction

Osimertinib, a third‐generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), provides marked clinical benefit for patients with EGFR‐activating mutations. Unfortunately, limited treatments exist for patients who acquire osimertinib resistance. We observed two ‘...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Rui, Hao, Shuai, Lu, Conghua, Zhang, Chong, Lin, Caiyu, Li, Li, Wang, Yubo, Hu, Chen, He, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266273/ https://www.ncbi.nlm.nih.gov/pubmed/32239624 http://dx.doi.org/10.1002/1878-0261.12682

Ejemplares similares

Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
por: Chen, Hengyi, et al.
Publicado: (2017)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC
por: Lu, Conghua, et al.
Publicado: (2022)

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling
por: Li, Li, et al.
Publicado: (2022)

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway
por: Li, Li, et al.
Publicado: (2016)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis
por: Weber, Stefan U, et al.
Publicado: (2008)

Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim
por: Meng, Jieru, et al.
Publicado: (2010)

Notch3 Cooperates With the EGFR Pathway to Modulate Apoptosis Through The Induction Of Bim
por: Konishi, Jun, et al.
Publicado: (2009)

BIM-mediated apoptosis and oncogene addiction
por: Li, Yulin, et al.
Publicado: (2016)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Lin, Caiyu, et al.
Publicado: (2021)

Bim plays apoptosis offense
por: Powell, Kendall
Publicado: (2007)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats
por: Wu, Qingjun, et al.
Publicado: (2020)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC
por: Incharoen, Pimpin, et al.
Publicado: (2019)

Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells
por: Heidari, N, et al.
Publicado: (2012)

Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib
por: Fan, WuQiang, et al.
Publicado: (2019)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
por: Zhai, Xiaoyang, et al.
Publicado: (2021)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

Induction of apoptosis by HBI‐8000 in adult T‐cell leukemia/lymphoma is associated with activation of Bim and NLRP3
por: Hasegawa, Hiroo, et al.
Publicado: (2016)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
por: Racherla, Kavya Sri, et al.
Publicado: (2023)

C1QTNF6 regulates cell proliferation and apoptosis of NSCLC in vitro and in vivo
por: Zhang, Wei, et al.
Publicado: (2021)

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations
por: Shi, Puyu, et al.
Publicado: (2019)

Myt3 suppression sensitizes islet cells to high glucose-induced cell death via Bim induction
por: Tennant, B R, et al.
Publicado: (2016)

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
por: Crowley, Fionnuala, et al.
Publicado: (2021)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
por: Piper-Vallillo, A.J., et al.
Publicado: (2022)

Implementation of Space Charge Forces in BimBim
por: Gottlob, Emmanuel
Publicado: (2017)

miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes
por: Qian, Li, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lcbuqmqr1lc9sj3srvght4894o